Darifenacin (Cipla USA Inc.)
Welcome to the PulseAid listing for the Darifenacin drug offered from Cipla USA Inc.. This Cholinergic Muscarinic Antagonist [EPC],Cholinergic Muscarinic Antagonists [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: | Cipla USA Inc. |
NON-PROPRIETARY NAME: | Darifenacin Hydrobromide |
SUBSTANCE NAME: | DARIFENACIN HYDROBROMIDE |
TYPE: | HUMAN PRESCRIPTION DRUG |
PHARMA CLASS: | Cholinergic Muscarinic Antagonist [EPC],Cholinergic Muscarinic Antagonists [MoA] |
ROUTE: | ORAL |
DOSAGE FORM: | TABLET, EXTENDED RELEASE |
MARKETING CATEGORY NAME: | ANDA |
START MARKETING DATE: | 2016-09-01 |
END MARKETING DATE: | 0000-00-00 |
Darifenacin HUMAN PRESCRIPTION DRUG Details:
Item Description | Darifenacin from Cipla USA Inc. |
LABELER NAME: | Cipla USA Inc. |
DEA SCHEDULE: |
|
ACTIVE STRENGTH: | 7.5(mg/1) |
START MARKETING DATE: | 2016-09-01 |
END MARKETING DATE: | 0000-00-00 |
PRODUCT ID: | 69097-431_cdecb9b2-7fa7-4803-8822-07e3125f2af8 |
PRODUCT NDC: | 69097-431 |
APPLICATION NUMBER: | ANDA207664 |
Other DARIFENACIN HYDROBROMIDE Pharmaceutical Manufacturers / Labelers: